Hematologic Malignancy
Mature B-Cell Non-Hodgkin Lymphoma
CI-CAN-00003259Explore in graph →
Hematologic792 active trials17 approved drugs43 evidence items
- NCIt
- C7056
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003259Explore in graph →
Clinical trials
2,506 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (393)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00015912 | Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00060112 | Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma | terminated | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00064246 | Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder | completed | Phase 1 / Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00089271 | 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00003970 | Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00077155 | Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00086944 | Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00098891 | MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00005950 | 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma | terminated | Phase 2 | 111 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00006473 | Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00777738 | Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia(WM2) | completed | Phase 2 | 34 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 18, 2013 | clinicaltrials |
| NCT01345357 | Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma | completed | Phase 1 | 24 | CephalonINDUSTRY | 2 | Jan 18, 2013 | clinicaltrials |
| NCT00363272 | Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT01606605 | Treatment Resistance Related With Gene Expression Profile of Diffuse Large B-cell Lymphoma | completed | — | 350 | Samsung Medical CenterOTHER | 1 | Jan 15, 2013 | clinicaltrials |
| NCT00101244 | SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma | terminated | Phase 1 | 31 | National Cancer Institute (NCI)NIH | 1 | Jan 14, 2013 | clinicaltrials |
| NCT00003166 | Bryostatin and Vincristine in B-Cell Malignancies | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Jan 11, 2013 | clinicaltrials |
| NCT00058305 | Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation | completed | Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2013 | clinicaltrials |
| NCT00891072 | Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2013 | clinicaltrials |
| NCT00017381 | Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma | completed | Early Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 9, 2013 | clinicaltrials |
| NCT00022581 | Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT00118170 | Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function | completed | Phase 1 | 150 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT00301795 | Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma | terminated | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT00902525 | Zevalin Twice in Aggressive Non-Hodgkin Lymphoma | terminated | Phase 2 | 25 | Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle LeucemieOTHER | 1 | Dec 31, 2012 | clinicaltrials |
| NCT00142181 | Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia | completed | Phase 2 | 27 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 21, 2012 | clinicaltrials |
| NCT00850499 | Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab | terminated | Phase 2 | 12 | Millennium Pharmaceuticals, Inc.INDUSTRY | 7 | Dec 12, 2012 | clinicaltrials |
| NCT00541424 | Combined CT Colonography and PET Imaging in Mantle Cell Lymphoma | withdrawn | — | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Dec 6, 2012 | clinicaltrials |
| NCT00636155 | EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | terminated | Phase 2 | 20 | David RizzieriOTHER | 1 | Nov 28, 2012 | clinicaltrials |
| NCT00513175 | Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia | completed | — | 44 | University of California, San FranciscoOTHER | 1 | Nov 9, 2012 | clinicaltrials |
| NCT00366275 | Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma | completed | Phase 2 | 64 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Oct 31, 2012 | clinicaltrials |
| NCT01054781 | Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL) | completed | Phase 2 | 91 | Samsung Medical CenterOTHER | 1 | Sep 27, 2012 | clinicaltrials |
| NCT00992134 | Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma | completed | Phase 2 | 41 | St. Bortolo HospitalOTHER | 1 | Sep 26, 2012 | clinicaltrials |
| NCT00209222 | Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL | unknown | Phase 3 | 360 | European Mantle Cell Lymphoma NetworkOTHER | 3 | Sep 10, 2012 | clinicaltrials |
| NCT00968331 | Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | terminated | Phase 2 | 25 | University of BolognaOTHER | 1 | Aug 27, 2012 | clinicaltrials |
| NCT00146055 | Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood | completed | Phase 2 | 60 | University of Michigan Rogel Cancer CenterOTHER | 1 | Aug 9, 2012 | clinicaltrials |
| NCT00772655 | Zevalin® First Line in Follicular Lymphoma | unknown | Phase 2 | 60 | Charite University, Berlin, GermanyOTHER | 0 | Aug 2, 2012 | clinicaltrials |
| NCT00822432 | Coproporphyrine Isomers and Methotrexate Elimination(COMETH) | completed | — | 85 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jul 31, 2012 | clinicaltrials |
| NCT00843050 | A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma | terminated | Phase 2 | 13 | Piramal Enterprises LimitedINDUSTRY | 2 | Jul 27, 2012 | clinicaltrials |
| NCT01558778 | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant | withdrawn | N/A | 0 | Roswell Park Cancer InstituteOTHER | 0 | Jul 9, 2012 | clinicaltrials |
| NCT00514475 | Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma | completed | Phase 2 | 160 | Oslo University HospitalOTHER | 1 | May 4, 2012 | clinicaltrials |
| NCT01263899 | A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies | completed | Phase 2 | 28 | S*BIOINDUSTRY | 2 | Apr 20, 2012 | clinicaltrials |
| NCT00799461 | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications | completed | Phase 3 | 1,337 | Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumOTHER | 1 | Mar 7, 2012 | clinicaltrials |
| NCT00475332 | Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar | terminated | Phase 2 | 2 | University of FloridaOTHER | 1 | Feb 15, 2012 | clinicaltrials |
| NCT00636792 | A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma(VERTICAL) | completed | Phase 2 | 73 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 13, 2012 | clinicaltrials |
| NCT00505232 | Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02)(LCM-04-02) | completed | Phase 2 | 30 | CABYCINDUSTRY | 1 | Jan 2, 2012 | clinicaltrials |
| NCT01302912 | Lymphoma in the Orbit | unknown | — | 50 | University of ZurichOTHER | 1 | Nov 4, 2011 | clinicaltrials |
| NCT00038623 | Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma | completed | Phase 2 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 2, 2011 | clinicaltrials |
| NCT01459887 | Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma | completed | Phase 3 | 278 | Shanghai CP Guojian Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 26, 2011 | clinicaltrials |
| NCT00907348 | Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma(REAL07) | unknown | Phase 2 | 49 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Oct 13, 2011 | clinicaltrials |
| NCT01009970 | Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma | unknown | Phase 2 | 50 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Oct 13, 2011 | clinicaltrials |
| NCT00530140 | Idiotypic Vaccination for Follicular Lymphoma Patients(FLIDVAX2006) | unknown | Phase 2 | 100 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Oct 6, 2011 | clinicaltrials |
Data updated 23 days agoSource updated Jan 25, 2013source: clinicaltrials